Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

5 evidence topics · 28 sources

Summary: what current options treat
  • Trofinetide is indicated in the United States for Rett syndrome in adults and pediatric patients 2 years of age and older, and its mechanism of action in Rett syndrome is unknown. An expert consensus of 25 respondents supports it as first-line therapy for eligible patients aged 2 years or older. The European Union authorization covers the neurobehavioural symptoms of Rett syndrome in patients aged 5 years and older.
  • The other options described in the sources address individual comorbidities: antiseizure medications for seizures; laxatives, acid suppression, and gastrostomy for gastrointestinal and nutritional problems; bracing and spinal surgery for scoliosis; physical activity, calcium, vitamin D, and bisphosphonates for bone health; selective serotonin reuptake inhibitors for anxiety; melatonin, trazodone, or clonidine for sleep; and physical, occupational, speech, and augmentative communication therapies.
Summary: size of the trofinetide effect
  • In the 12-week randomized, double-blind, placebo-controlled study that established efficacy (Study 1 in the prescribing information), participants aged 5 to 20 years were randomized to trofinetide (N=93) or placebo (N=94). The least squares mean change in RSBQ total score was -4.9 with trofinetide and -1.7 with placebo, a difference of -3.2 (95% CI -5.7 to -0.6; p = 0.018; Cohen's d effect size 0.37). The mean CGI-I score at week 12 was 3.5 against 3.8, a difference of -0.3 (95% CI -0.5 to -0.1; p = 0.003; effect size 0.47). The key secondary endpoint, the Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist Social Composite score, changed by -0.1 against -1.1 (P = 0.0064; effect size 0.43).
  • The European Medicines Agency described the improvements as small and considered them relevant for a rare and serious disorder.
  • In open-label extensions, the mean RSBQ improvement from the LAVENDER baseline was -7.3 (1.62) and -7.0 (1.61) at week 40 of LILAC (154 participants) for those given trofinetide and placebo in LAVENDER, and -11.8 (2.45) at week 104 of LILAC-2 (77 participants).
Summary: trofinetide tolerability and discontinuation
  • In Study 1, diarrhea occurred in 82% of participants receiving trofinetide and 20% receiving placebo, and vomiting in 29% and 12%. Across Study 1 and long-term studies, 85% of trofinetide-treated patients had diarrhea, and 49% had persistent or recurrent diarrhea despite dose interruptions, reductions, or antidiarrheal therapy; 51% used antidiarrheal medication in Study 1. Weight loss greater than 7% occurred in 12% receiving trofinetide and 4% receiving placebo in Study 1, and 2.2% discontinued for weight loss in long-term studies. Aspiration and aspiration pneumonia have been reported after vomiting.
  • The two sources give different withdrawal counts for the 12-week study: the prescribing information reports 18 patients (19%) receiving trofinetide who withdrew because of adverse reactions, most often diarrhea (15%), and the trial publication reports 16 (17.2%) receiving trofinetide and 2 (2.1%) receiving placebo who withdrew because of a treatment-emergent adverse event, with diarrhea leading to discontinuation in 12 (12.9%). The study was completed by 70 (75.3%) participants receiving trofinetide and 85 (90.4%) receiving placebo.
  • In LILAC, diarrhea occurred in 74.7% and was the most common adverse event leading to withdrawal (21.4%). In a follow-up of 227 caregivers, the median dose at week 1 was 36.0% of the target dose, rising to over 80% from week 10, 55.2% of patients took the full recommended daily dose, and diarrhea incidence ranged from 23% to 50% during weeks 1 to 12. The expert consensus recommends starting at 25% to 50% of the weight-banded dose and titrating every 1 to 2 weeks.
Summary: age range of trofinetide evidence
  • The randomized evidence comes from participants aged 5 to 20 years, and LILAC enrolled females aged 5 to 21 years. Use in patients aged 2 to 4 years is supported by the randomized study together with pharmacokinetic and safety data in 15 patients aged 2 to 4 years. The open-label DAFFODIL study enrolled 15 participants, in whom diarrhea occurred in 80.0% and vomiting in 53.3%. Safety and effectiveness below 2 years of age have not been established, and the European Union authorization applies from 5 years of age.
  • In natural history data, regression began between 12 and 30 months of age in more than 80% of individuals, and the median age of skill loss was 3 years or younger for 46 of 51 developmental skills.
Summary: evidence gaps in supportive care
  • Epilepsy: no randomised controlled trials of specific anticonvulsants have been conducted in Rett syndrome, no systematic study has shown one medication or class to be superior, and no definite recommendation is available. Drug-resistant epilepsy affects 20% to 40% of those with seizures, and surgical treatment is generally ineffective. Of those with classic Rett syndrome and a history of epilepsy in one cohort, 74 (12%) were seizure free and off antiseizure medication at last contact. In a cohort of 27 subjects carrying an MECP2 (14) or CDKL5 (13) variant, cannabidiol reduced seizures in 18 of 27 (66.6%) without reaching statistical significance.
  • Gastrointestinal and nutrition: 3 (5.9%) neurologists and 4 (8.2%) pediatricians surveyed ranked gastrointestinal management among their five most important treatment goals. Among individuals at risk of suboptimal weight, all-cause mortality was higher after gastrostomy placement (hazard ratio 4.07, 95% CI 1.96 to 8.45), and its long-term impact is described as unclear.
  • Scoliosis: scoliosis often does not respond to orthotics. A Rett syndrome diagnosis predicted higher odds of complications (odds ratio 1.98) in admissions for posterior spinal fusion, and the rate of death was lower in those who had scoliosis surgery than in those without surgery (hazard ratio 0.30, 95% CI 0.12 to 0.74).
  • Bone health: panel members noted the lack of evidence for the efficacy and safety of bisphosphonates in Rett syndrome, and the bisphosphonate indication statement reached 17/23 (73.9) agreement.
  • Anxiety and sleep: no systematic studies of anxiolytics and no anxiety management guidelines exist, and the Natural History Study was not designed to assess their efficacy or safety. Sleep management has no treatment algorithm. In a 4-week double-blind, placebo-controlled crossover trial of melatonin, sleep-onset latency decreased to 19.1 (SE 5.3) minutes during the first 3 weeks, and the long-term effects of chronic use in pediatric patients are unknown.
  • Rehabilitation: one publication identified nine physical therapy approaches and reported clinical benefit from them despite an absence of strong research evidence. Across 16 communication intervention studies, intervention was provided to a total of 100 participants. Little evidence specific to Rett syndrome defines whether ongoing, episodic, intensive, or consultative therapy models are optimal at different ages.